10x Genomics
254 hedge funds and large institutions have $3.91B invested in 10x Genomics in 2022 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 96 increasing their positions, 85 reducing their positions, and 92 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 85
2.91% more ownership
Funds ownership: 88.75% → 91.66% (+2.9%)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
19% less funds holding
Funds holding: 314 → 254 (-60)
34% less call options, than puts
Call options by funds: $13.9M | Put options by funds: $21.1M
38% less capital invested
Capital invested by funds: $6.29B → $3.91B (-$2.38B)
61% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 92
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Generation Investment Management
London,
United Kingdom
|
+$136M |
| 2 |
SIM
SRS Investment Management
New York
|
+$132M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$107M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$53.1M |
| 5 |
JP Morgan Chase
New York
|
+$48.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$121M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$81.9M |
| 3 |
1WCM
12 West Capital Management
New York
|
-$65.8M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$55.1M |
| 5 |
FAM
Fred Alger Management
New York
|
-$25M |
TXG Hedge Fund Activity: Q2 2022 in Review
254 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q2 2022, worth a combined $3.91B — down 38% from $6.29B a quarter earlier.
Sellers outnumbered buyers: 92 funds closed out of TXG and 36 opened new positions — a net loss of 56 holders — while 85 trimmed existing stakes and 96 added.
The largest buyer was Generation Investment Management, opening a new position worth an estimated $136M. The largest seller was BlackRock, cutting an estimated $121M.
- 254 institutional investors held 10x Genomics (TXG) as of Q2 2022, down from 314 in Q1 2022.
- Funds reported $3.91B of 10x Genomics stock for Q2 2022, down 38% quarter-over-quarter.
- 36 funds opened new 10x Genomics positions in Q2 2022 and 92 closed out, a net change of -56 holders.
- The largest 10x Genomics buyer in Q2 2022 was Generation Investment Management, an estimated $136M added.
- The largest 10x Genomics seller in Q2 2022 was BlackRock, an estimated $121M sold.
Based on aggregated 13F filings for Q2 2022.